Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study
Helicobacter · 2023
DOI: 10.1111/hel.12946 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2023. Verfasst von Wei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shang…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Peptic Ulcer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
The aim of this pilot study was to evaluate the efficacy and safety of intravenous use esomeprazole, metronidazole, and/or levofloxacin in the treatment of Helicobacter pylori ( H. pylori )‐associated peptic ulcer complications.
Methods
Inpatients with peptic ulcer complications who were not able to take oral medicine were randomly assigned to three groups: triple therapy (esomeprazole, levofloxacin, metronidazole) and dual therapy (esomeprazole, levofloxacin/metronidazole) for 7 days. After intravenous treatment, all patients received open‐label oral esomeprazole 20 mg bid for another 1 month. All subjects were followed up for gastroscopy at the seventh day of intravenous treatment to confirm the ulcer healing and 13 C‐urea breath test to confirm successful H. pylori eradication 4–6 weeks after completion of oral esomeprazole therapy.
Results
The H. pylori eradication rate of both LEV‐dual therapy (33.3%, 95% CI: 9.7%–70.0%) and MTZ‐dual therapy (50%, 95% CI: 21.5%–78.5%) was significantly lower than that of triple therapy (95%, 95% CI: 71.1%–97.4%) ( p = .003, .016). There were no significant differences in the adverse effects among all treatment groups, and the adverse effects were rare.
Conclusions
The intravenous triple regimen, consisting of proton‐pump inhibitor, metronidazole, and levofloxacin, could be considered in patients of H. pylori ‐associated peptic ulcer complications if oral medicine cannot be provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Emergency Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Hong Lu
Förderung
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Gui, Q., Chen, J., Yu, D., Su, W., Zhu, C., Liang, X., & Lu, H. (2023). Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study. Helicobacter. https://doi.org/10.1111/hel.12946
Vancouver
Zhang W, Gui Q, Chen J, Yu D, Su W, Zhu C, et al. Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study. Helicobacter. 2023. doi:10.1111/hel.12946
BibTeX
@article{Zhang2023,
author = {Zhang, Wei and Gui, Qian and Chen, Jinnan and Yu, Dazhong and Su, Wenyu and Zhu, Changqing and Liang, Xiao and Lu, Hong},
title = {Intravenous metronidazole‐, levofloxacin‐containing triple therapy for treating patients with Helicobacter pylori ‐related active peptic ulcer complications: A pilot study},
journal = {Helicobacter},
year = {2023},
doi = {10.1111/hel.12946}
}
EUVIMED